Rapid Acting Antidepressants. Advances in Pharmacology Volume 89

Table of Contents

Part I
Neurobiology of ketamine effects

- Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission

Allie J. Widman and Lori L. McMahon

- Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition

Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson

- The role of eEF2 kinase in the rapid antidepressant actions of ketamine

Kanzo Suzuki and Lisa M. Monteggia

Part II
The rapid therapeutic effects of ketamine

- Clinical overview of NMDA-R antagonists and clinical practice

Pasha A. Davoudian and Samuel T. Wilkinson

- Ketamine for depression clinical issues

Syed Z. Iqbal and Sanjay J. Mathew

- Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence

Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah

- Neurobiological biomarkers of response to ketamine

Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr

- Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants

Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets

- The emergence of ketamine as a novel treatment for posttraumatic stress disorder

Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney

Part III
Novel rapid-acting antidepressant mechanisms related to ketamine

- mGlu2/3 receptor as a novel target for rapid acting antidepressants

Shigeyuki Chaki

- Involvement of muscarinic receptor mechanisms in antidepressant drug action

Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin

- The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions

Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey